Alvotech ALVO

Morningstar Rating
$5.45 −0.17 (3.02%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ALVO is trading at a LOCK|!h^J< premium.
Price
$5.46
Fair Value
LOCK|<!TmP<n
Uncertainty
LOCK|Ts LV#$>
1-Star Price
LOCK|.bxBgb%
5-Star Price
LOCK|t&Xpw
Economic Moat
LOCK|&r
Capital Allocation
—

News

Trading Information

Previous Close Price
$5.62
Day Range
$5.43–5.70
52-Week Range
$2.94–9.05
Bid/Ask
$5.42 / $5.73
Shares Outstanding
356.82M
Market Cap
$1.94B
Volume/Avg
750,933 / 985,571

Key Statistics

Price/Earnings (Normalized)
59.73
Price/Sales
3.38
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
1,460

Valuation

Metric
ALVO
Price/Earnings (Normalized)
59.73
Price/Book Value
—
Price/Sales
3.38
Price/Cash Flow
—
Price/Earnings
ALVO

Financial Strength

Metric
ALVO
Quick Ratio
0.83
Current Ratio
1.65
Interest Coverage
0.75
Quick Ratio
ALVO

Profitability

Metric
ALVO
Return on Assets (Normalized)
−11.60%
Return on Equity (Normalized)
—
Return on Invested Capital (Normalized)
−4.50%
Return on Assets
ALVO

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|yvc%k#MLOCK|npM^$67B
Teva Pharmaceutical Industries Ltd
TEVA
LOCK|x%<<>r>vLOCK|n&kR$46B
Haleon PLC ADR
HLN
LOCK|q!<wrRLOCK|lH$38B
Zoetis Inc Class A
ZTS
LOCK|f$THPLZ@LOCK|HjV$29B
Viatris Inc
VTRS
LOCK|@C<@$YZLOCK|##R$20B
Elanco Animal Health Inc
ELAN
LOCK|!<kLOCK|GM$11B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|#RX$&j$LOCK|>@$10B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|Ln@Z<$LOCK|Fy$7B
Prestige Consumer Healthcare Inc
PBH
LOCK|&@$W?^LOCK|!$&z$2B
Perrigo Co PLC
PRGO
LOCK|<lrv%b&LOCK|?!$2B

Sponsor Center